Browse the evidence

In China, there was no significant association between white rice intake and diabetes risk (HR: 1.05; 95% CI: 0.78-1.41, p for trend=0.38).

Dietary recommendations regarding white rice may differ in China compared to other regions.

No significant associations were found between GLP-1 receptor agonists or SGLT2 inhibitors and risk of sepsis, abscess, gangrene, or other infections.

Practitioners can be reassured about the lack of infection risk associated with these medications.

Obesity is projected to affect over half of the global population by 2035.

Healthcare providers should prepare for increased obesity-related challenges.

Advances in omics technologies have enabled the identification of molecular subtypes and candidate biomarkers for obesity.

Utilizing omics technologies can enhance personalized approaches to obesity treatment.

The net financial impact to Medicare was estimated to be savings of $715 million over 10 years.

Healthcare policymakers should recognize the potential cost savings associated with semaglutide for Medicare.

Availability of semaglutide in Medicare for all FDA-approved indications would yield net savings ranging from $1.04 billion to $412 million over 10 years.

Healthcare providers should advocate for the inclusion of semaglutide in Medicare to maximize economic and health benefits.

In 2022, 1 in 8 people in the world were living with obesity.

Practitioners should be aware of the significant prevalence of obesity.

Obesity was recognized as a disease by the German Bundestag on July 3, 2020.

This recognition may influence treatment protocols and funding for obesity management.

There is a lack of studies comparing adverse events across different populations for glucagon-like peptide-1 receptor agonists.

Further research is needed to assess the safety of glucagon-like peptide-1 receptor agonists across diverse populations.

Further research is needed to assess the long-term safety of Tirzepatide, particularly regarding cardiovascular outcomes.

Practitioners should be aware of the need for ongoing evaluation of Tirzepatide's long-term safety profile.

Interdisciplinary collaboration and communication between anaesthetists, surgeons, general practitioners, and endocrinologists are required to further investigate and establish preoperative guidelines for safe GLP-1 agonist use.

Healthcare teams should work together to create and follow guidelines for managing patients on GLP-1 agonists in surgical settings.

62% of protein supplement users were male.

Practitioners should note the gender distribution in protein supplement use.

42% of protein supplement users were aged 25–34.

Targeted educational initiatives can be focused on this age group.

Up to half of patients with diabetes mellitus are undiagnosed when referred for elective surgery.

Healthcare providers should consider screening for diabetes in patients scheduled for elective surgery.

The 2015 law for strengthening health promotion and prevention defines goals for T2D.

Legislators and health organizations should be aware of the defined goals for T2D.

The law does not present strategies or financial and personnel prerequisites for effective primary and secondary prevention.

Health policymakers need to develop strategies and allocate resources for effective prevention.

Obesity prevalence is projected to grow by 40% in the next decade.

Health professionals should prepare for increased obesity-related health issues.

A BMI greater than 30 kg/m^2 is considered diagnostic for obesity.

Practitioners should use BMI as a key metric for diagnosing obesity.

The fraction of available calories from protein in the US food supply has decreased by ~1% since the early 1970s.

Awareness of changes in dietary composition over time is important for nutritional guidance.

More people around the world now have obesity than suffer from starvation.

This indicates a need for urgent public health interventions to address obesity.

The energy available in the food supply increased much more than population needs.

This suggests that dietary guidelines may need to be adjusted to account for excess energy availability.

Substantial investments in coordinated nutrition and agricultural research are needed to transform the food system.

This highlights the importance of policy and research in addressing obesity and food security.

The mean cumulative intervention costs for the intensive lifestyle intervention (ILI) were $11,275 per person, compared to $887 for standard diabetes support and education (DSE), resulting in ILI costing $6,666 more per person than DSE.

Practitioners should consider the higher costs associated with intensive lifestyle interventions compared to standard education.

The additional quality-adjusted life years (QALYs) gained by ILI were not statistically significant, with values of 0.17 and 0.16 measured by SF-6D and Feeling Thermometer, respectively.

The lack of statistically significant QALY gains suggests that intensive lifestyle interventions may not provide additional health benefits over standard education.